

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6182447

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
KATHOLIEKE UNIVERSITEIT LEUVEN	09/22/2014
LIFE SCIENCES RESEARCH PARTNERS VZW	09/22/2014
RECEIVING PARTY DATA	
Name:	IMCYSE SA
Street Address:	AVENUE DE L'HOPITAL, 1, GIGA-B34
City:	SART-TILMAN
State/Country:	BELGIUM
Postal Code:	B-4000
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16848086
CORRESPONDENCE DATA	
Fax Number:	(703)816-4100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7038164000
Email:	mgaszner@nixonvan.com, anorris@nixonvan.com
Correspondent Name:	NIXON & VANDERHYE, P.C.
Address Line 1:	901 NORTH GLEBE ROAD
Address Line 2:	SUITE 1100
Address Line 4:	ARLINGTON, VIRGINIA 22203
ATTORNEY DOCKET NUMBER:	2752.0130
NAME OF SUBMITTER:	MIKLOS GASZNER
SIGNATURE:	/Milkos Gaszner, Reg. No. 61,314/
DATE SIGNED:	07/02/2020
Total Attachments: 3	
source=Assignment 4 License#page1.tif	
source=Assignment 4 License#page2.tif	
source=Assignment 4 License#page3.tif	

THIS DEED is made the 22nd day of September 2014.

BETWEEN:

- (1) **The Katholieke Universiteit Leuven**, ("**KULeuven**"), legal entity following publication of its incorporation act and organic regulations in the annexes to the Belgian Official Gazette of 1 July 1970, according to the law of 12 August 1911, made public in the Belgian Official Gazette of 21/22 August thereafter, last modified by law of 28 May 1971, made public in the Belgian Official Gazette of 17 July thereafter, with administrative office at B-3000 Leuven (Belgium), Oude Markt 13, hereby represented by K.U. Leuven Research and Development, with offices at B-3000 Leuven (Belgium), Waaistraat 6, being represented by its signatories referred to below ;
- (2) **Life Sciences Research Partners VZW** ("**LSRP**"), a Belgian non-profit organization having as company number 0435 768 243, having its administrative office at Campus Gasthuisberg, Onderwijs en Navorsing, 9e verdieping, bus 913, Herestraat 49, B-3000 Leuven (Belgium), mandated by the Katholieke Universiteit Leuven to represent the Center for Molecular and Vascular Biology ("**CMVB**"), having offices at Campus Gasthuisberg, K.U. Leuven, Herestraat 49, B-3000 Leuven (Belgium), LSRP being represented by its signatories referred to below ;
- (3) **ImCyse SA** ("**the Licensee**"), a company incorporated in Belgium as company number 0828.385.542 and whose registered office is at and whose registered office is at B-4000 Sart-Tilman (Belgium), avenue de l'Hôpital, 1, GIGA-B34 being represented by its signatories referred to below.

KULeuven and LSRP have granted to the Licensee an exclusive, worldwide licence under the patents and patent applications set out in the Schedule below by a license agreement with as effective date July 15th, 2010 and as entry date December 29th, 2010.

Schedule

All national and regional phases, including divisional applications, of PCT application PCT/EP2007/007165 (WO2008017517) filed on 13.08.2007, entitled "**Immunogenic peptides and their use in immune disorders**", including Australian patent AU2007283731, Australian application AU2014200368, Canadian application CA2660605, European applications EP07801643.3, EP11187012.7, EP11187013.5 and EP11187014.3, Japanese application JP2009523209 and US patent application US12/377,048.

All national and regional phases, including divisional applications, of PCT application PCT/BE2008/000010 (WO2009100505) filed on 14.02.2008, entitled "**Immunogenic peptides and their use in transplantation**", including Australian patent AU2008350785, Canadian application CA2715517, European application EP08706161.0 and US application US12/735,744.

All national and regional phases, including divisional applications, of PCT application PCT/EP2009/051806 (WO2009101206) filed on 16.02.2009 entitled "**Strategies to prevent and/or treat immune responses to soluble allofactors**", including Australian patent AU2009214040, Canadian application CA2724440, European application EP09710097.8 and US application US12/735,739.

All national and regional phases, including divisional applications, of PCT application PCT/EP2009/051804 (WO2009101205) filed on 16.02.2009, entitled "**Immunogenic control of tumours and tumour cells**", including Australian patent AU2009214039, Australian application AU2013270496, Canadian application CA2715488, European applications EP09710780.9, EP13150813.7 and EP13151001.8, Hong Kong application HK14101218.8. and US application US12/735,740.

All national and regional phases, including divisional applications, of PCT application PCT/EP2009/051803 (WO2009101204) filed on 16.02.2009, entitled "**Elimination of immune responses to viral vectors**", including Australian patent AU2009214038, Australian application AU2013263773, Canadian application CA2715484, European applications EP09711066.2 and EP1315100.0, Hong Kong application HK14101089.4 and HK14101088.5 and US application US12/735,754.


All national and regional phases, including divisional applications, of PCT application PCT/EP2009/051808 (WO2009101208) filed on 16.02.2009, entitled "**Immunotherapy targeting intracellular pathogens**", including Australian patent AU2009214042, Australian application 2014202556, Canadian application CA2715611, European application EP09711135.5 and EP13187209.5 and US application US12/735,742.

All national and regional phases, including divisional applications, of PCT application PCT/EP2009/051807 (WO2009101207) filed on 16.02.2009, entitled "**CD4+ T-cells with cytolytic properties**", including Australian application AU2009214041, Canadian application CA2715536, European application EP09711368.2 and US applications US12/735,741 and US14/135,630.

All national and regional phases, including divisional applications, of PCT application PCT/BE2013/000006 (WO2013113076) filed on 30.01.2013, entitled "**Modified epitopes for boosting CD4+ T-Cell responses**", including national and regional phases in Australia, Brazil, Canada, China, Europe, India, South-Korea, Japan, Russia, USA and South Africa.

AS WITNESS the parties have caused this Deed to be duly executed on the day and year first above written.


EXECUTED as a Deed
by KULEuven
acting by


Paul VAN DUN
General Manager


Prof. Dr. ir. Koenraad DEBACKERE [Function]
MANAGING DIRECTOR

and by

EXECUTED as a Deed
by LSRP
acting by Ch. Byse


Director
[Function]

EXECUTED as a Deed
by ImCyse SA

acting by

Jean-Marie Saint-Remy,
Director

Investpartner SPRL,
Director, represented by Marc Foidart

